Klinická farmakologie a farmacie – 4/2020

KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2020; 34(4): 159–166 / www.klinickafarmakologie.cz 166 HLAVNÍ TÉMA Specifika metabolismu léčiv v dětském věku Tandler PJ, Zaya MJ. Developmental expression of the ma‑ jor human hepatic CYP3A enzymes. J Pharmacol Exp Ther. 2003; 307(2): 573–582. 18. Johnsrud EK, Koukouritaki SB, Divakaran K, Brunengraber LL, Hines RN, McCarver DG. Human hepatic CYP2E1 expression du‑ ring development. J Pharmacol Exp Ther. 2003; 307(1): 402–407. 19. Gade C, Dalhoff K, Petersen TS, et al. Higher chlorzoxa‑ zone clearance in obese children compared with nonobese peers. Br J Clin Pharmacol. 2018; 84(8): 1738–1747. 20. Ingelman‑Sundberg M. Genetic polymorphisms of cy‑ tochrome P450 2D6 (CYP2D6): clinical consequences, evo‑ lutionary aspects and functional diversity. Pharmacogeno‑ mics J. 2005; 5(1): 6–13. 21. Buzková H, Pechandová K, Slanar O, Perlík F. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population. Cell Biochem Funct. 2008; 26(1): 76–81. 22. Armstrong SC, Cozza KL. Pharmacokinetic drug interacti‑ ons of morphine, codeine, and their derivatives: theory and clinical reality, Part II. Psychosomatics. 2003; 44(6): 515–520. 23. Stamer UM, Stüber F. Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype. Anaesthesia. 2007; 62(12): 1294–1295. 24. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, Mc‑ Cracken. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD J Am Acad Child Ado‑ lesc Psychiatry 2007; 46(2): 242–251. 25. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Phar‑ macogenetics of morphine poisoning in a breastfed neonate of a codeine‑prescribed mother. Lancet. 2006; 368(9536): 704. 26. Ginsberg G, Slikker W Jr, Bruckner J, Sonawane B. Expre‑ ssion Incorporating children’s toxicokinetics into a risk fra‑ mework. Environ Health Perspect. 2004; 112(2): 272–283. 27. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004; 308(3): 965–974. 28. Cashman JR, Zhang J. Human flavin‑containing monooxy‑ genases. Annu Rev Pharmacol Toxicol. 2006; 46: 65–100. 29. Krueger SK, Williams DE. Mammalian flavin‑containing monooxygenases: structure/function, genetic polymor‑ phisms and role in drug metabolism. Pharmacol Ther. 2005; 106, 357−387. 30. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. Human hepatic flavin‑containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res.2002; 51(2): 236–243. 31. McCarver DG, Hines RN. The ontogeny of human drugme‑ tabolizing enzymes: Phase II conjugation enzymes and regu‑ latory mechanisms. J Pharmacol Exp Ther. 2002; 300: 361–366. 32. FDA: Drug Development and Drug Interac‑ tions: Table of Substrates, Inhibitors and Indu‑ cers. Content current as of : 03/10/2020 Availab‑ le from: <http://www.scielo.br/ scielo.php?script=sci_ arttext & pid=S2358-04292014000300105 & lng=en & nr‑ m=iso>. 33. Hines RN, McCarver DG. The ontogeny of human drug­ ‑metabolizing enzymes: phase I oxidative enzymes. J Phar‑ macol Exp Ther. 2002; 300(2): 355–360. 34. Ladumor MK, Bhatt DK, Gaedigk A, et al. Ontogeny of Hepatic Sulfotransferases and Prediction of Age‑Dependent Fractional Contribution of Sulfation in Acetaminophen Meta‑ bolism. Drug Metab Dispos. 2019; 47(8): 818–831. 35. Sunderland JM. Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. Am. J., DiS. Child. 1959; 97: 761–767. 36. Jancova P, Anzenbacher P, Anzenbacherova E. Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Pa‑ lacky Olomouc Czech Repub. 2010; 154(2): 103–116. 37. Pacifici GM, Säwe J, Kager L, Rane A. Morphine glucuro‑ nidation in human fetal and adult liver. Eur J Clin Pharmacol. 1982; 22(6): 553–558. 38. Lim SY, Pettit RS. Pharmacokinetic considerations in pe‑ diatric pharmacotherapy. Am J Health Syst Pharm. 2019; 76(19): 1472–1480. 39. Kodidela S, Kumar SS, Uppugunduri CR. Developmental pattern of hepatic drug‑metabolizing enzymes in pediatric population and its role in optimal drug treatment. Arch Med Health Sci 2017; 5: 115–122. 40. Cummings ED, Kong EL, Edens MA. Gray Baby Syndrome. [Updated 2020 Sep 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https:// www.ncbi.nlm.nih.gov/books/NBK448133/. 41. Golka K, Selinski S. NAT2 Genotype and Isoniazid Medica‑ tion in Children. EBioMedicine. 2016; 11: 11–12. 42. Knowles JW, Xie W, Zhang Z, et al. Identification and vali‑ dation of N‑acetyltransferase 2 as an insulin sensitivity gene. J Clin Invest. 2015 Apr; 125(4): 1739–1751. 43. Kamel AM, Ebid GT, Moussa HS. N‑Acetyltransferase 2 (NAT2) polymorphism as a risk modifier of susceptibility to pediatric acute lymphoblastic leukemia. Tumour Biol. 2015; 36(8): 6341–6348. 44. Johnson TN. The development of drug metabolising en‑ zymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology. 2003; 192(1): 37–48. 45. Fakhoury M, Litalien C et al. Localization and mRNA expre‑ ssion of CYP3A and P‑glycoprotein in human duodenum as a function of age. Drug Metab Dispos. 2005; 33(11): 1603–1607. 46. Lee KB, Ang L, Yau WP, Seow WJ. Association between Metabolites and the Risk of Lung Cancer: A Systematic Lite‑ rature Review and Meta‑Analysis of Observational Studies. Metabolites. 2020; 10(9): 362. 47. Johnson TN. The development of drug metabolising en‑ zymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology. 2003; 192(1): 37–48. 48. Martin JRN, SLHD Guideline: Newborn Infants Exposed to SSRI / SNRI Antidepressant Medication during Pregnancy and Lactation, Sydney Local Health Distric, 2020. 49. Kelly EL, Poon S, Madadi P, Koren G. Neonatal Benzo‑ diazepines Exposure during Breastfeeding. J Pediatr. 2012; 161(3): 448–451. 50. Kimmel MC, Meltzer‑Brody S. Safety of infant exposure to antidepressants and benzodiazepines through breastfee‑ ding, UpToDate, 2020. 51. Lee J. Antiepileptic Drugs in Children: Current Concept. J Korean Neurosurg Soc. 2019; 62(3): 296–301. 52. Sridharan K, Daylami AA, Ajjawi R, Ajooz HAMA. Drug­ ‑Induced Liver Injury in Critically Ill Children Taking Antiepi‑ leptic Drugs: A Retrospective Study. Curr Ther Res Clin Exp. 2020; 92: 100580. 53. Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth. 2019; 122(4): 448–459. 54. Krajčová A, Waldauf P, Anděl M, Duška F. Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. Crit Care. 2015; 19: 398. 55. Hassen M, Bhikoo R, Clint J, Yazied C. Unintentional di‑ ethylene glycol poisoning following the consumption of a shared alcoholic beverage. African Journal of Nephrolo‑ gy. 2018; 21(1): 8–11. 56. O‘Brien KL, Selanikio JD et al. Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poiso‑ ning. Acute Renal Failure Investigation Team. JAMA. 1998; 279(15): 1175–1180. 57. Kriegel C, Festag M, Kishore RSK, Roethlisberger D, Schmi‑ tt G. Pediatric Safety of Polysorbates in Drug Formulations. Children (Basel). 2019; 7(1): 1. 58. Valeur KS, Holst H, Allegaert K. Excipients in Neonatal Me‑ dicinal Products: Never Prescribed, Commonly Administered. Pharmaceut Med. 2018; 32(4): 251–258. 59. Bartelink IH, Rademaker CM, Schobben AF, van den An‑ ker JN. Guidelines on paediatric dosing on the basis of deve‑ lopmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006; 45(11): 1077–1097. 60. Eidelman C, Abdel‑Rahman S. Pharmacokinetic consi‑ derations when prescribing in children. Int J Pharmacoki‑ net. 2018; 1(1): 69–80.